PDCD1 and hepatocellular carcinoma: In the mouse HCC model, the survival rate of PD-1 inhibitor immunotherapy combined with radiotherapy was significantly improved, which greatly inhibited the growth of tumor, increased CD8+ T cells, and restored their function [219].